Mallinckrodt PLC

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes innovative specialty pharmaceutical brands. The Specialty Generics segment relates to niche specialty generic drugs and active pharmaceutical ingredients. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Mallinckrodt investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securiti.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Mallinckrodt plc (MNK) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) investors concerning the Company's possible violations of federal securities laws. In October 2020, Mallinckrodt filed for Chapter 11 bankruptcy protection while agreeing to settle its role in the U.S. opioid crisis by making nine payments equaling $1.7 billion over eight years to an opioid-victims compensation trust. In June 2022,.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Mallinckrodt plc (MNK) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. In October 2020, Mallinckrodt filed for Chapter 11 bankruptcy protection while agreeing to settle its role in the U.S. opioid crisis by making nine payments equaling $1.7 bil.

The Law Offices of Frank R. Cruz Announces Investigation of Mallinckrodt plc (MNK) on Behalf of Investors

Shares of Mallinckrodt PLC MNK, +4.35% rose 5.5% in afternoon trading Friday, after the drugmaker disclosed that it will once again delay the $200 million opioid-settlement payment by a week, following discussions with the Opioid Master Disbursement Trust II. The payment was originally scheduled for June 16, but the company has kept delaying payment a week at a time, as its board of directors continues to hold talks with stakeholders about its capital position and financial obligations.

Mallinckrodt stock rises after disclosure of another one-week delay in the $200 million opioid-settlement payment

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Mallinckrodt plc (NYSE American: MNK) (OTC: MNKPF) between June 17, 2022 and June 14, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2023. SO WHAT: If you purchased Mallinckrodt securities.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Mallinckrodt plc Investors with Over $1 Million in Losses to Secure Counsel Before Important Deadline in Securities Class Action – MNK, MNKPF

NEW YORK--(BUSINESS WIRE)---- $MNK #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (NYSE: MNK) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mallinckro.

Calling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

Alibaba

Levi Strauss

Mallinckrodt PLC shares MNK, -5.26% surged 9% in the premarket trading after the drug maker and distributor said it was open to proposed transactions from debt holders as it keeps delaying a payment under an opioid settlement.

Levi Strauss shares tumble on outlook cut, Mallinckrodt and Alibaba shares rise and more stocks on the move

Mallinckrodt PLC MNK shares surged in the extended session Thursday after the Dublin-based drug maker and distributor said it was open to proposed transactions as it keeps delaying a payment under an opioid settlement. Shares rallied as much as 15%, and were last up around 9% in late Thursday activity, following a 5.3% decline top close Thursday at $1.08 a share.

Mallinckrodt open to proposed transactions as it struggles to pay opioid settlement; stock rallies

Mallinckrodt, the financially troubled pharmaceutical company, is in discussions with a compensation trust for opioid victims as it seeks to potentially reduce the amount of settlement payments by as much as $1 billion, according to people familiar with the matter.

Mallinckrodt in Talks to Cut Opioid Settlement by Up to $1 Billion

Drug maker Mallinckrodt MNK, on Monday said it paid roughly $17 million in interest that was due last Tuesday, as it tries to keep up with bill payments following a $1.7 billion opioid settlement following allegations it helped fuel the nation's opioid crisis. The payment, Mallinckrodt said, arrived within a grace period of five business days, keeping a default at bay.

Mallinckrodt makes late interest payment

Mallinckrodt PLC MNK, -15.69% disclosed Friday that it has decided to further delay the $200 million opioid-settlement payment by a week. The payment was originally due on June 16, before payment was delayed to June 23, and is now delayed to June 30.

Mallinckrodt delays $200 million opioid-settlement payment by another week

Generic-drug maker Mallinckrodt MNK, +17.69% on Wednesday said it set aside more than $3.4 million in executive retention bonuses in the event of a possible filing for yet another bankruptcy. The move is latest sign of difficulty for the company, which has struggled to pay its bills in the wake of a $1.7 billion opioid settlement following allegations it helped propel the nation's opioid crisis.

Mallinckrodt readies retention bonuses in event of bankruptcy filing

Shares of Mallinckrodt PLC MNK, +24.14% shot up 26.5% in afternoon trading, after the drug maker said it reached an agreement to delay a $200 million opioid-settlement payment by a week. The stock's rally comes after it closed Thursday below the $1 mark for the first time, at 87 cents.

Mallinckrodt stock soars, after disclosure that $200 million opioid-settlement payment was delayed by a week

Mallinckrodt is seeking to postpone a $200 million opioid settlement payment, Bloomberg News reported on Thursday citing people with knowledge of the matter.

Mallinckrodt looking to delay $200 million opioid payment - Bloomberg News

Shares of Mallinckrodt PLC MNK dropped 4.8% in premarket trading Thursday, after the drug maker disclosed that it decided not to make interest payments that were due on June 15 on two senior secured notes. The company said failing to make the interest payments would constitute and event of default if the failure continues for a period of 30 days, for both the 11.50% First Lien Senior Secured Notes due 2028 and the 10.00% Second Lien Senior Secured Notes due 2029.

Mallinckrodt stock falls after decision not to make interest payments, as drug maker continues to mull potential bankruptcy

– Two scientific poster presentations at EASL 2023 will detail findings of Mallinckrodt's latest research providing insight into the therapeutic effect of TERLIVAZ® from baseline, and the clinical management of adults with HRS with rapid reduction in kidney function1 – DUBLIN , June 15, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that two scientific posters detailing Mallinckrodt's latest research findings on the clinical outcomes of treatment with TERLIVAZ® (terlipressin) for injection and clinical management criteria for adult patients with hepatorenal syndrome (HRS) will be presented at the European Association for the Study of the Liver (EASL) Congress 2023 in Vienna, Austria, taking place June 21-24, 2023. Both posters will be presented on June 24, 2023, 9:00 a.m.

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) Congress 2023

Mallinckrodt (NYSEMKT: MNK ) stock is falling hard on Monday after the company received letters from concerned noteholders. These letters have holders of notes due in 2027 and 2029 expressing issues with the company's current financial situation.

Why Is Mallinckrodt (MNK) Stock Down 23% Today?

Shares of Mallinckrodt PLC MNK, -5.41% tumbled 22.0% in premarket trading Monday, after the drug maker disclosed that certain debt holders proposed another bankruptcy filing given the company's financial position. The proposal comes as the company is required to make a $200 million payment on June 16, as part of its opioid settlement.

Mallinckrodt evaluating another possible bankruptcy filing as $200 million opioid settlement pay comes due

Drugmaker Mallinckrodt plc said on Monday some of its lenders have proposed that the company consider another bankruptcy filing as it nears a deadline to pay a $200 million opioid settlement.

Drugmaker Mallinckrodt says lenders propose another bankruptcy filing

Pharmaceutical company Mallinckrodt Plc is considering options including filing for bankruptcy again as a $200 million opioid settlement payment is due within weeks, the Wall Street Journal reported on Friday citing people familiar with the matter.

Drugmaker Mallinckrodt may file for bankruptcy again -WSJ

– Findings from two clinical studies in adults with HRS involving rapid reduction in kidney function1 provide insight into the use of terlipressin among patients with comorbidities and varying baseline characteristics2,3 – DUBLIN , June 1, 2023 /PRNewswire/ --  Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical studies in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 treated with TERLIVAZ® (terlipressin) for injection at the American Transplant Congress (ATC) 2023, taking place in San Diego, Calif. from June 3-7, 2023.

Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023

NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), the New York City-based investment advisor to clients with financial interests in Mallinckrodt Plc. (“Mallinckrodt” or the “Company”) (NYSE: MNK), today issued an open letter (the “Letter”) to the Company's Board of Directors, given the Company's continued failure to make required write-downs of asset values where expenses are evidenced, in apparent violation of GAAP ASC 350/360.

Buxton Helmsley Issues Letter to Mallinckrodt Plc. Regarding Continued Evidentially False Statements of Financials

Mallinckrodt plc (NYSE:MNK ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Dan Speciale – Chief Investor Relations Officer Siggi Olafsson – Chief Executive Officer Bryan Reasons – Chief Financial Officer Conference Call Participants Rishi Parekh – JP Morgan Operator Good day and thank you for standing by. Welcome to the Mallinckrodt First Quarter 2023 Earnings Announcement.

Mallinckrodt plc (MNK) Q1 2023 Earnings Call Transcript

Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest Reports First Quarter Net Sales of $424.6 Million; Net Loss of $249.3 Million; Adjusted EBITDA of $123.5 Million; Diluted Loss Per Share of $18.93 and Adjusted Diluted Earnings Per Share of $1.68 Increased Cash on Hand to $480.0 Million and Reduced Exposure to Interest Rate Volatility Through Interest Rate Cap Agreement, Demonstrating Ongoing Focus on Disciplined Balance Sheet Management Reaffirmed 2023 Net Sales and Adjusted EBITDA Guidance Conference Call and Webcast Today at 8:30 a.m. ET DUBLIN , May 9, 2023 /PRNewswire/ --  Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported results for the first quarter ended March 31, 2023.1 "Mallinckrodt had a solid start to the year.

Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

– Findings from two clinical study presentations in adults with HRS involving rapid reduction in kidney function1 provide insight into the appropriate use of terlipressin for the care of critically ill patients2,3 – DUBLIN , May 8, 2023 /PRNewswire/ --  Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical studies for adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 treated with TERLIVAZ® (terlipressin) for injection at Digestive Disease Week® (DDW) 2023, taking place in Chicago, Ill. from May 6-9.

Mallinckrodt Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at Digestive Disease Week (DDW) 2023

News for Mallinckrodt PLC Stock (MNK)